Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.

SG&A Expenses: A Decade of Biotech Financial Strategies

__timestampBioCryst Pharmaceuticals, Inc.CRISPR Therapeutics AG
Wednesday, January 1, 201474610005114000
Thursday, January 1, 20151304700013403000
Friday, January 1, 20161125300031056000
Sunday, January 1, 20171393300035845000
Monday, January 1, 20182951400048294000
Tuesday, January 1, 20193712100063488000
Wednesday, January 1, 20206792900088208000
Friday, January 1, 2021118818000102802000
Saturday, January 1, 2022159371000102464000
Sunday, January 1, 202321389400076162000
Monday, January 1, 202472977000
Loading chart...

Igniting the spark of knowledge

A Decade of SG&A Evolution: CRISPR Therapeutics AG vs. BioCryst Pharmaceuticals, Inc.

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, from 2014 to 2023, the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc. have showcased intriguing trends. BioCryst Pharmaceuticals, Inc. has seen a staggering 2,768% increase in SG&A expenses, peaking at $213.9 million in 2023. In contrast, CRISPR Therapeutics AG's expenses grew by 1,389%, reaching $102.8 million in 2021 before a decline to $76.2 million in 2023. This divergence highlights BioCryst's aggressive expansion strategy, while CRISPR's recent cost-cutting measures suggest a strategic pivot. As these companies navigate the competitive biotech arena, understanding their financial strategies offers valuable insights into their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025